Core Laboratories Files Registration Statement for Initial Public Offering

Strategic Insights -

Core Laboratories, a Netherlands-based company, has announced its plans for an initial public offering (IPO) of 2.5 million common shares, with the possibility of an additional 375,000 shares through an over-allotment option. The net proceeds from the offering will be used to repay outstanding indebtedness and repurchase outstanding preferred stock. Jefferies & Company, Inc. and Morgan Keegan & Company, Inc. have been appointed as the managing underwriters for the IPO. The company's business spans petroleum reservoir rock and fluids analyses, environmental testing, and the manufacture of integrated octane measurement equipment.

Key Takeaways:

  • Core Laboratories, a Netherlands-based company, has filed a registration statement with the Securities and Exchange Commission for an initial public offering of 2.5 million common shares.
  • The company plans to use the net proceeds from the offering to repay outstanding indebtedness and repurchase outstanding preferred stock.
  • Jefferies & Company, Inc. and Morgan Keegan & Company, Inc. will manage the offering as underwriters.
  • The company's business encompasses petroleum reservoir rock and fluids analyses, environmental testing, and the manufacture of integrated octane measurement equipment.
  • A registration statement has been filed but has not yet become effective, and securities may not be sold until the statement becomes effective.
  • Certain nonmanagement shareholders will grant the underwriters an over-allotment option to purchase up to 375,000 additional shares.
  • Richard L. Bergmark, Core Laboratories' representative, can be contacted to obtain copies of the Prospectus.

Statistics:

  • 2.5 million: the number of common shares being offered by Core Laboratories in the initial public offering.
  • 375,000: the number of additional shares that can be purchased through the over-allotment option.
  • 5295 Hollister Road, Houston, Texas 77040: the address of Richard L. Bergmark's office for Prospectus inquiries.
  • 713-460-9600: the phone number of Richard L. Bergmark's office for Prospectus inquiries.

Sources:

  • PRNewswire, Amsterdam, Netherlands, September 5, 1995.
  • Regulation D, Securities Act of 1933, 17 CFR 230.405.
  • Core Laboratories, N.V.